Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials.

Moreover, our analysis revealed other safety outcomes, including increased alanine aminotransferase, increased blood creatine phosphokinase, and abnormal hepatic function, although these findings did not reach statistical significance.

also in 111,027 other papers